Supplements
curcumin improves ulcerative colitis remission
In plain terms: Does turmeric help ulcerative colitis?
Part of: 🧪 turmeric & curcumin
Yes, as an add-on. Layered on top of standard therapy, curcumin improves remission rates in ulcerative colitis across several trials — one of its better-evidenced uses. It's an adjunct, not a replacement for your medication.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
One of curcumin's better gut claims: added on top of standard 5-ASA therapy, curcumin improves clinical response and remission in ulcerative colitis across several RCT meta-analyses. It's an adjunct to conventional treatment, not a standalone — and one prominent recent trial used a curcumin-indigo combination, so not all the benefit is curcumin alone.
The evidence (11)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Mohseni S, Tavakoli A, Ghazipoor H, Pouralimohamadi N, Zare R, Rampp T, Shayesteh M, Pasalar M 2025 · Frontiers in nutrition | meta-analysis | supports | moderate | Systematic review/meta-analysis of 13 placebo-controlled RCTs of curcumin in IBD (mostly UC patients); curcumin significantly improved clinical remission and response in UC, though no superiority over placebo for CD clinical/endoscopic remi |
| Zheng T, Wang X, Chen Z, He A, Zheng Z, Liu G 2020 · J Gastroenterol Hepatol | meta-analysis | supports | moderate | Meta-analysis of RCTs: adjuvant curcumin improved remission/response in ulcerative colitis vs standard therapy alone. |
| Xu R, Zhang Z, Li Y, Wu Z 2026 · Frontiers in medicine | meta-analysis | mixed | moderate | Network meta-analysis, 24 RCTs/1,491 patients across 14 dietary supplements for UC; curcumin showed higher IBDQ (quality of life) scores vs conventional drugs/placebo (MD=25.80) but was NOT among the supplements showing significant advantag |
| Goulart RA, Barbalho SM, Rubira CJ, Araújo AC, Lima VM, Rogerio Leoni B, Guiguer EL 2020 · Expert Rev Gastroenterol Hepatol | meta-analysis | supports | moderate | SR+meta-analysis: curcumin improved clinical remission rates in ulcerative colitis as adjunct therapy. |
| Jiang H, Li G, Xie L, Zhang N, Huang Y, Liang X, Guo F, Jiang Q, Liao Z 2025 · Nutrients | animal | supports | low | DSS-induced UC mouse model; curcumin+tryptophan combination outperformed either agent alone on weight loss, disease activity index, and colon length, with restored gut barrier function and microbiota. |
| Peng Z, Li D, Wu N, Wang XY, Sun GX, Gao HB, Li HX 2025 · Explore (New York, N.Y.) | meta-analysis | supports | high | Updated systematic review/meta-analysis of 8 RCTs, 482 UC patients; adjunctive curcumin significantly improved clinical remission (RR=2.33, 95% CI 1.25-4.34) and clinical/endoscopic improvement, with a non-significant trend toward higher en |
| Zhao Y, Bao M, Niu W 2026 · Frontiers in medicine | RCT | supports | moderate | Prospective multicenter double-blind RCT, 159 moderate-to-severe UC patients (vedolizumab alone n=76 vs vedolizumab+curcumin n=83) over 26 weeks; combination group had significantly higher clinical remission rates at both 14 and 26 weeks pl |
| Gangwar T, Poonia N, Subudhi RN, Arora V 2025 · Naunyn-Schmiedeberg's archives of pharmacology | observational | supports | low | Narrative review of phytoconstituents (resveratrol, curcumin, quercetin, berberine, hesperidin) in UC; states experimental and clinical evidence suggests these compounds can reduce clinical manifestations, induce/sustain remission via anti |
| Huang B, An H, Chen L, Lin H, Wu H, Li R, Su Y, Lin J, Shi D 2025 · Frontiers in pharmacology | meta-analysis | supports | moderate | Network meta-analysis of 34 RCTs (n=2,854) comparing mesalazine alone vs mesalazine + 8 TCM formulations including CurQD (curcumin+indigo naturalis); CurQD ranked highest (SUCRA 96.7%) for symptom improvement, direct comparison RR=2.67 (95% |
| Ben-Horin S, Salomon N, Karampekos G, Viazis N, Lahat A, Ungar B, Eliakim R, Kuperstein R, Kriger-Sharabi O, Reiss-Mintz H, Yanai H, Dotan I, Zittan E, Maharshak N, Hirsch A, Weitman M, Mantzaris GJ, Kopylov U 2024 · Clin Gastroenterol Hepatol | RCT | mixed | moderate | Double-blind RCT: a curcumin-QingDai (indigo) combination induced response/remission in active UC — benefit not attributable to curcumin alone. |
| Yin J, Wei L, Wang N, Li X, Miao M 2022 · J Ethnopharmacol | meta-analysis | supports | moderate | SR+meta-analysis: adjuvant curcumin was efficacious and safe in ulcerative colitis. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.